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Background
Soluble guanylate cyclase (sGC) is the key enzyme in the
NO-sGC-cGMP signaling cascade crucial in regulating
the cardiovascular system. Low output of this system
causes hypertension and acute heart failure, which are
the leading causes of death globally.
Mammalian sGC is a heterodimer. Each of the two
homologous subunits (a and b) contains three domains:
an N-terminal regulatory domain (HNOX: Heme Nitric
oxide OXygen), a central dimerization HNOX associated
(HNOXA) and coiled-coil (CC) domain, and a C-term-
inal catalytic domain (GC).
The enzyme is basally active, but NO binding to the
heme group in the b subunit’s regulatory domain
enhances sGC catalytic output several hundred fold.
The exact mechanism by which the regulatory domain
relays the NO activation signal to the catalytic domain
remains elusive. Furthermore, it has been proposed
that the HNOX regulatory domain inhibits the activity
of the catalytic GC domain [1]. Winger et al. showed
that the GC heterodimer by itself exhibits catalytic
activity in the presence of Mg
2+ and Mn
2+[1]. On the
contrary, Wedel et al. propose that additional amino
acids are required for dimerization, folding, and cataly-
tic activity [2].
We aim to test the hypothesis that additional domains
are necessary for full activity of the catalytic domain by
combining mutagenesis, activity assays, fluorescence
spectroscopy, Small-Angle X-ray Scattering (SAXS), and
protein crystallography.
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Figure 1 Full-length sGC and C-terminal truncated constructs abGC and abCC-GC.
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We have chosen a divide-and-conquer approach to
study sGC catalysis. Here, we report the recombinant
expression and purification of bovine C-terminal con-
structs “abGC” and “abCC-GC” in E. coli (Figure 1).
Preliminary activity measurements for these constructs
i nt h ep r e s e n c eo fM g
2+ show that abCC-GC exhibits
higher level of catalytic activity than abGC (4-fold).
This suggests that additional domains are necessary for
full catalytic activity. To our knowledge this is the first
report that attributes catalytic activity to the abCC-GC
heterodimer in the presence of Mg
2+.
Conclusion
The C-terminal sGC constructs abGC and abCC-GC,
both exhibit catalytic activity in the presence of Mg
2+.
Higher levels of activity of abCC-GC as compared to
abGC hint at structural differences between the two
constructs that will be characterized using protein X-ray
crystallography and small-angle X-ray scattering.
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